Comparative activity of ertapenem and piperacillin–tazobactam in a murine systemic infection model with Bacteroides fragilis and Escherichia coli, Page 1 of 1
Chapin-RobertsonK.,
EdbergS.1991; Measurement of antibiotics in human body fluids: techniques and significance. In Antibiotics in Laboratory Medicine , 3rd edn. p 295–366 Edited by
LorianV.
Baltimore, MD: Williams & Wilkins;
Dela PenaA. S.,
AspergerW.,
KockerlingF.,
RazR.,
KafkaR.,
WarrenB.,
ShivaprakashM.,
VrijensF.,
GiezekH.other authors2006; Efficacy and safety of ertapenem versus piperacillin-tazobactam for the treatment of intra-abdominal infections requiring surgical intervention. J Gastrointest Surg 10:567–574[CrossRef]
FreireichE. J.,
GehanE. A.,
RallD. P.,
SchmidtL. H.,
SkipperH. E.1966; Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother Rep 50:219–244
GoldsteinE. J. C.,
SnydmanD. R.2004; Intra-abdominal infections: review of the bacteriology, antimicrobial susceptibility and the role of ertapenem in their therapy. J Antimicrob Chemother 53:Suppl 2ii29–ii36
GoldsteinE. J.,
CitronD. M.,
CherubinC. E.1991; Comparison of the inoculum effect of cefoxitin and other cephalosporins and of β -lactamase inhibitors and their penicillin-derived components on the Bacteroides fragilis group. Antimicrob Agents Chemother 35:1868–1874[CrossRef]
KönigC.,
SimmenH. P.,
BlaserJ.1998; Bacterial concentrations in pus and infected peritoneal fluid - implications for bactericidal activity of antibiotics. J Antimicrob Chemother 42:227–232[CrossRef]
NCCLS2003; Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically , approved standard. , 6th edn.M7–A6 Wayne, PA: National Committee for Clinical Laboratory Standards;
NCCLS2004; Methods for Antimicrobial Susceptibility Testing for Anaerobic Bacteria , approved standard. , 6th edn.M11–A6 Wayne, PA: National Committee for Clinical Laboratory Standards;
NixD. E.,
MajumdarA. K.,
DiNubileM. J.2004; Pharmacokinetics and pharmacodynamics of ertapenem: an overview for clinicians. J Antimicrob Chemother 53:Suppl 2ii23–ii28
SantosK. V.,
DinizC. G.,
CoutinhoS. C.,
ApolônioA. C. M.,
Sousa-GaiaL. G.,
NicoliJ. R.,
FariasL. M.,
CarvalhoM. A. R.2007; In vitro activity of piperacillin/tazobactam and ertapenem against Bacteroides fragilis and Escherichia coli in pure and mixed cultures. J Med Microbiol 56:798–802[CrossRef]
SolomkinJ. S.,
YellinA. E.,
RotsteinO. D.,
ChristouN. V.,
DellingerE. P.,
TelladoJ. M.,
MalafaiaO.,
FernandezA.,
ChoeK. A.other authors2003; Ertapenem versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections: results of a double-blind, randomized comparative phase III trial. Ann Surg 237:235–245
StearneL. E.,
van BoxtelD.,
LemmensN.,
GoessensW. H.,
MoutonJ. W.,
GyssensI. C.2004; Comparative study of the effects of ceftizoxime, piperacillin, and piperacillin-tazobactam concentrations on antibacterial activity and selection of antibiotic-resistant mutants of Enterobacter cloacae and Bacteroides fragilis in vitro and in vivo in mixed-infection abscesses. Antimicrob Agents Chemother 48:1688–1698[CrossRef]